Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Zigeuner, R; Ratschek, M; Langner, C.
Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas.
BJU INT. 2005; 95(3): 315-318.
Doi: 10.1111/j.1464-410X.2005.05290.x
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Langner Cord
- Zigeuner Richard
- Co-Autor*innen der Med Uni Graz
- Ratschek Manfred
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- OBJECTIVE: To investigate the presence of Kit (CD117), a transmembrane tyrosinase-kinase receptor, in primary and metastatic renal cell carcinomas (RCCs) and upper urinary tract transitional cell carcinomas (TCCs). MATERIALS AND METHODS: In human neoplasia, overexpression of Kit has been related to cell proliferation, differentiation, adhesion and control of apoptosis. If present, Kit may provide a suitable target for tumour therapy. Formalin-fixed and paraffin-embedded specimens of 180 primary and 58 metastatic RCCs and 54 upper urinary tract TCCs were immunostained for Kit (CD117) using a tissue microarray technique. RESULTS: In RCCs, immunoreactivity for CD117 was detected in only two of 23 (9%) chromophobe tumours, whereas all 137 conventional and 20 papillary subtypes, and metastatic RCC tissues, lacked CD117 immunoreactivity. In TCCs, CD117 expression of <10% cancer cells was found in two of 53 (4%) cases. Stromal mast cells served as a positive control and showed specific immunostaining. CONCLUSION: Kit immunoreactivity is infrequent in both RCCs and upper urinary tract TCCs. Thus, routine screening of tumour tissues for Kit by immunohistochemistry appears to be cost-ineffective and cannot be recommended. Moreover, the lack of substantial Kit immunoreactivity in both primary and metastatic carcinomas does not provide a rationale to investigate imatinib mesylate therapy in clinical trials including patients with advanced disease.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Carcinoma, Renal Cell - metabolism
- Carcinoma, Transitional Cell - metabolism
- Female - metabolism
- Humans - metabolism
- Immunohistochemistry - metabolism
- Kidney Neoplasms - metabolism
- Male - metabolism
- Middle Aged - metabolism
- Proto-Oncogene Proteins c-kit - metabolism
- Urologic Neoplasms - metabolism
- Find related publications in this database (Keywords)
- renal cell carcinoma
- transitional cell carcinoma
- Kit
- CD117
- immunohistochemistry
- tissue microarray